Effect of Levocarnitine on the Therapeutic Efficacy of Conventional Therapy in Children with Dilated Cardiomyopathy: Results of a Randomized Trial in 29 Children

Paediatric Drugs
Yuwen WangCheng Wang

Abstract

The effect of levocarnitine supplementation has not been evaluated in children with dilated cardiomyopathy (DCM). The aim of this study was to explore the effect of oral levocarnitine supplementation in pediatric patients with DCM. Twenty-nine children with DCM (17 male, 12 female, aged 1 month to 13 years) were divided into two groups according to a simple randomization: control group (n = 10) and experimental group (n = 19). All children were given oral hydrochlorothiazide, enalapril, and spironolactone; additionally, patients with cardiac function of NYHA grade IV were given oral digoxin, and patients with intractable heart failure were given intravenous dopamine and dobutamine. When cardiac function was restored to NYHA grade II-III, patients were given oral metoprolol. Patients in the experimental group received add-on treatment with oral levocarnitine solution (50-100 mg/kg/day). Patients were followed up at 1, 3, 6 and 12 months. Left ventricular ejection fraction (EF), short axis shortening (FS), and left atrium (LA) and left ventricle (LV) diameters were measured at different times during the follow-up. The children with DCM were followed up for 1 year. Cardiac function was significantly improved in the experimental gr...Continue Reading

References

Apr 4, 2002·Drugs·Ricardo Rocha, Gordon H Williams
May 29, 2003·Current Pharmaceutical Biotechnology·A Evangeliou, D Vlassopoulos
Jan 23, 2004·Cardiovascular Research·Marc van BilsenGer J van der Vusse
Oct 19, 2006·JAMA : the Journal of the American Medical Association·Jeffrey A TowbinSteven E Lipshultz
Jul 31, 2007·Journal of the American College of Cardiology·James N KirkpatrickRoberto M Lang
Apr 20, 2010·Nutrition & Metabolism·Judith L FlanaganQian Garrett
Nov 10, 2012·Translational Research : the Journal of Laboratory and Clinical Medicine·Santica M MarcovinaHossein Ardehali
Mar 30, 2013·European Journal of Heart Failure·Aldo P MaggioniUNKNOWN Heart Failure Association of the European Society of Cardiology (HFA)
Apr 9, 2013·European Journal of Pharmacology·Athina A StrilakouCharis A Liapi
Sep 17, 2013·Circulation·Peta M A AlexanderUNKNOWN National Australian Childhood Cardiomyopathy Study
Jul 15, 2015·International Journal of Cardiology·Mingxian ChenShenghua Zhou

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Methods Mentioned

BETA
genotyping
biopsy

Software Mentioned

SPSS

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.